【跨年重磅】专利胜诉!诺和诺德GLP-1双喜临门筑高墙

药见未来
Jan 01

导语:在2025年的最后十天里,全球代谢病领域的巨头诺和诺德(Novo Nordisk)接连斩获两项决定性胜利。一是口服版Wegovy在美国获批上市,二是司美格鲁肽在中国赢得专利终审胜诉。这两大事件不仅是诺和诺德的胜利,更是全球GLP-1市场格局的分水岭。摆脱针头:首个口服减肥版司美格鲁肽正式启航2025年12月22日,美国FDA正式批准了Wegovy®(司美格鲁肽50mg)口服片剂用于成年人的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10